Core Viewpoint - A class action securities lawsuit has been filed against Merck & Co., Inc. due to alleged securities fraud impacting investors between February 3, 2022, and February 3, 2025 [1] Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors affected by misleading information regarding Merck's expected revenue of $11 billion from Gardasil sales by 2030 [2] - The complaint highlights that Merck's optimistic forecasts for Gardasil's growth in China were based on claims of successful consumer activation and education efforts [2] - On February 4, 2025, Merck announced it would not meet the projected $11 billion in sales, ceasing shipments to China to reduce inventory due to lower-than-expected demand [2] Group 2: Stock Impact - Following the announcement on February 4, 2025, Merck's stock price dropped from $99.79 to $90.74, a decline of over 9% in one day [2] Group 3: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until April 14, 2025, to request appointment as lead plaintiff, although participation does not require this role [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 4: Firm Background - Levi & Korsinsky has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the U.S. [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Merck & Co., Inc. securities between February 3, 2022, and February 3, 2025, about the April 14, 2025, deadline to become a lead plaintiff in a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Merck securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 14, 2025 [2]. - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3]. Group 2: Case Background - The lawsuit alleges that throughout the Class Period, Merck provided misleading information regarding expected revenue of $11 billion from Gardasil sales by 2030, while concealing adverse facts about demand visibility in China [4]. - Defendants reportedly made overly optimistic statements about Gardasil's growth potential in China, despite lacking insight into actual demand among targeted populations, leading to inflated inventory levels [4].

Group 1: Merck's Capvaxive Approval - The European Commission has approved Merck's 21-valent pneumococcal conjugate vaccine, Capvaxive, for the prevention of invasive pneumococcal disease and pneumococcal pneumonia in individuals aged 18 years and above [1][2] - Capvaxive targets serotypes responsible for approximately 84% of all invasive pneumococcal diseases in older adults in the United States, including eight serotypes not covered by currently licensed vaccines [2][3] - The approval was based on safety and immunogenicity data from the STRIDE clinical program, including phase III studies comparing Capvaxive to PCV20 [3][4] Group 2: Market Context and Competitors - Year to date, Merck's shares have decreased by 11.5%, while the industry has seen a rise of 4.4% [2] - Pfizer is a key competitor in the pneumococcal conjugate vaccine space, marketing Prevnar 20 and Prevnar 13, which generated $6.4 billion in combined sales in 2024 [5][7] - Sanofi has expanded its collaboration with SK bioscience to develop next-generation pneumococcal conjugate vaccines, including a 21-valent PCV for pediatric populations [8][9] - Vaxcyte is developing a 31-valent PCV, VAX-31, which is in mid-to-late-stage studies for preventing invasive pneumococcal disease in both pediatric and adult populations [10]

Core Viewpoint - Merck is facing challenges with its leading drug Keytruda due to future patent losses, yet the company is experiencing revenue growth and exploring new opportunities for expansion [1][9]. Financial Performance - In the last quarter of 2024, Merck reported a 9% revenue growth, reaching $15.6 billion, with Keytruda contributing $7.8 billion and achieving an organic growth rate of 21% [2]. - Keytruda accounted for 50% of Merck's sales last quarter, highlighting its significant role in the company's revenue [3]. Product Pipeline and Future Potential - Merck is developing a subcutaneous version of Keytruda, which could extend patent protection until 2040, potentially mitigating revenue loss from the original drug [3]. - The company has other promising products, including Gardasil, which could generate $11 billion by 2030, despite recent underwhelming demand [6]. - Winrevair, approved for pulmonary arterial hypertension, is projected to generate $6 billion by 2029, with a peak potential of $11 billion, indicating strong future growth prospects [7]. - Merck has secured rights to an experimental weight loss drug, which could tap into a massive market projected to exceed $100 billion, representing a long-term growth opportunity [8]. Investment Consideration - Merck's stock is currently trading at a modest 14 times its trailing earnings, suggesting a good margin of safety for investors [10]. - Despite concerns surrounding Keytruda and Gardasil, management's proactive strategies and the promising product pipeline may present a compelling investment opportunity [9][10].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Merck & Co., Inc. related to misleading statements about Gardasil sales and is encouraging affected investors to participate in a federal securities class action [2][4]. Group 1: Legal Investigation and Class Action - The law firm is urging investors who suffered losses exceeding $100,000 in Merck between February 3, 2022, and February 3, 2025, to contact them for legal options [1]. - There is an April 14, 2025, deadline for investors to seek the role of lead plaintiff in the class action against Merck [2]. - The complaint alleges that Merck and its executives violated federal securities laws by making false statements regarding Gardasil's expected revenue and demand in China [4]. Group 2: Financial Performance and Market Reaction - Merck reported a 3% decline in GARDASIL/GARDASIL 9 sales, totaling $8.6 billion for the fourth quarter and full year of 2024 [5]. - Following the announcement of the sales decline and a decision to pause shipments of Gardasil into China, Merck's stock price dropped by $9.05 per share, or 9.1%, closing at $90.74 on February 4, 2025 [6].

Core Viewpoint - Merck has entered into an exclusive licensing agreement with Jiangsu Hengrui Pharmaceuticals for the development and marketing of HRS-5346, an investigational oral small-molecule Lipoprotein(a) inhibitor [1][2]. Group 1: Licensing Deal Details - Merck will acquire global rights (excluding Greater China) for HRS-5346, paying an upfront cash payment of $200 million and up to $1.77 billion in milestone payments, along with royalties on future sales [2][3]. - The deal is expected to close in the second quarter, pending customary closing conditions and regulatory approvals [3]. Group 2: Health Implications - Elevated levels of Lipoprotein(a) are a significant risk factor for cardiovascular diseases, affecting approximately 1.4 billion people globally [4]. Group 3: Strategic Context - This licensing agreement marks Merck's third collaboration with Chinese biotech firms, following previous multi-billion dollar deals with Hansoh Pharma and LaNova Medicines [7]. - The strategy aims to diversify Merck's revenue base, which is heavily reliant on Keytruda, accounting for nearly 46% of total revenues in 2024 [8]. - The trend of big pharma companies seeking partnerships in China reflects a broader industry movement towards accessing new drugs at attractive valuations [9].

Core Viewpoint - A class action lawsuit has been filed against Merck & Co., Inc. concerning allegations of securities fraud and unlawful business practices [2][4]. Group 1: Lawsuit Details - The lawsuit involves claims that Merck and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Investors who purchased Merck securities during the Class Period have until April 14, 2025, to request to be appointed as Lead Plaintiff [2]. Group 2: Financial Impact - On July 30, 2024, Merck reported a significant reduction in demand for its HPV vaccination Gardasil in China, leading to higher inventory levels and potential shipment shortfalls [4]. - Following this announcement, Merck's stock price dropped by $12.53 per share, or 9.81%, closing at $115.25 per share [5]. - On February 4, 2025, Merck announced it would not meet the previously forecasted $11 billion sales target for Gardasil by 2030, leading to another stock price decline of $9.05 per share, or 9.07%, closing at $90.74 per share [5].

Group 1 - The Schall Law Firm has initiated a class action lawsuit against Merck & Co., Inc. for alleged violations of the Securities Exchange Act of 1934 [1][4] - The lawsuit pertains to investors who purchased Merck's securities between February 3, 2022, and February 3, 2025, and encourages them to contact the firm before April 14, 2025 [2] - The complaint alleges that Merck made false and misleading statements regarding the demand for its product Gardasil, particularly in China, while concealing negative facts about inventory levels [4] Group 2 - The lawsuit claims that Merck's public statements were materially misleading, leading to investor damages when the truth about the company's situation was revealed [4] - The Schall Law Firm specializes in securities class action lawsuits and represents investors globally [5]

NEW YORK, March 24, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Merck & Co., Inc. (NYSE: MRK).Shareholders who purchased shares of MRK during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/merck-co-inc-loss-submission-form/?id=137692&from=4CLASS PERIOD: February 3, 2022 to Febru ...

NEW YORK, March 21, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Merck & Co., Inc. ("Merck" or the "Company") (NYSE: MRK) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Merck investors who were adversely affected by alleged securities fraud between February 3, 2022 and February 3, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/merck-co-inc-lawsuit-submissio ...